Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.
Drastically cut down patent review times by focusing on the most relevant claim. Drug patent searches now allow you to identify the exact claim location of your hit sequences and the accompanying claim text directly from the results page!
Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.
Fast track designation (FTD) is a process used by the U.S. Food and Drug Administration (FDA) tofacilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.